monomethyl

Monomethyl fumarate is a potent agonist of GPR109A .

Hexaethylene glycol monomethyl ether, a PEG-based PROTAC linker, facilitates the synthesis of PROTACs[1].

Nonaethylene glycol monomethyl ether, a PEG-based PROTAC linker, facilitates PROTAC synthesis[1].

Octaethylene glycol monomethyl ether, a PEG-based linker, serves as an essential component in the synthesis of PROTACs[1].

Pentaethylene glycol monomethyl ether (PEG-MME) is a PEG-based PROTAC linker, which is employed for the synthesis of PROTACs[1].

Tetraethylene glycol monomethyl ether, a PEG-based PROTAC linker, is employed for the synthesis of PROTACs[1].

Vat-Cit-PAB-Monomethyl Dolastatin 10 is an ADC linker-conjugated drug designed to deliver potent antitumor activity through Monomethyl Dolastatin 10, a potent tubulin inhibitor, connected via the Vat-Cit-PAB (ADC linker).

Monomethyl fumarate-D3 is a deuterium labeled Monomethyl fumarate (T12095).

Monomethyl itaconate serves as a copolymerization agent and is an active metabolite of the prodrug SCD-153. Additionally, it has been detected in U. maydis. This compound has applications in the creation of copolymeric hydrogels for producing methotrexate-containing polymer disks and is also utilized in synthesizing thrombin inhibitors.

Monomethyl fumarate-D2 is the deuterated form of Monomethyl fumarate, which is an active metabolite of Dimethyl fumarate (DMF) and serves as an effective GPR109A agonist. Monomethyl fumarate (T12095) holds potential in various neuroprotective pathways and models of other retinal diseases.

Monomethyl sebacate is a biochemical.

Pinosylvin monomethyl ether (Standard) is a reference standard for research and analysis in studies involving Pinosylvin monomethyl ether. Pinosylvin monomethyl ether is an aromatic compound demonstrating inhibitory activity against A2780, J774, and HEK293 cells.

Koaburaside monomethyl ether is a natural product of Croton, Euphorbiaceae. The catalog number is TN4393 and the CAS number is 41514-64-1. Koaburaside monomethyl ether can be used as a reference standard.

18:1 Monomethyl PE is an alkyl phosphate ester.

(4R,5S)-MonomethylauristatinE intermediate-6 is an intermediate reactant in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity and is widely utilized as the cytotoxic component in antibody-drug conjugates (ADC Cytotoxin).

MonomethylauristatinE intermediate-8 is an intermediate compound in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) acts as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

MonomethylauristatinE intermediate-10 is an intermediate used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs) [ADC Cytotoxin].

MonomethylauristatinE intermediate-17 is an intermediate compound used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) functions as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

Isopropylene glycol monomethyl ether acetate is a bioactive chemical.

Monomethyl adipate is a biochemical.

Hematoporphyrin monomethyl ether is a porphyrin photosensitizer that can be used in studies of port wine stains.

Compound 7, or Raloxifene 6-Monomethyl Ether, is a derivative of Raloxifene that effectively inhibits estrogen receptor α. It also displays the inhibitory effects on MCF-7 cells, with an IC50 of 250 nM and a pIC50 of 6.6.

Raloxifene 4-Monomethyl Ether (Compound 37) is a Raloxifene derivative that inhibits estrogen receptor α, suppressing MCF-7 cell activity with an IC50 of 1 μM and a pIC50 of 6.

Monomethyl auristatin E (MMAE) (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.